Sebia FLC Outperforms Freelite® in Clinical Specificity

Fewer false positives. Better interpretation. Greater confidence.
A 2023 peer-reviewed study from Washington University School of Medicine, in collaboration with Mayo Clinic, reveals that the Sebia Serum Free Light Chain (sFLC) assay delivers significantly higher clinical specificity than the FreeLite® assay—especially in patients who present with multiple myeloma-like symptoms but do not have Plasma Cell Dyscrasias (PCDs).

Key findings:

• Sebia FLC assay correctly identified 87.5% of non-PCD patients as within normal range vs. just 68.7% with Freelite®, reducing false positives and unnecessary follow-ups.
• In patients with chronic kidney disease, fewer abnormal κ/λ results were reported when using renal-specific reference intervals—4.5% out-of-range with Sebia vs. 13.6% with Freelite®
• Discordance in κ/λ ratios: 31.3% of Freelite® results were outside normal limits (all high), while Sebia had just 12.5% out-of-range, with more balanced deviations above and below RI.

Clinical implications:

• Improved specificity translates to fewer unnecessary tests, referrals, and patient anxiety.
• More consistent interpretation using platform-appropriate reference intervals.
• Supports equitable diagnostics by reducing kidney-related result distortions, which often impact underserved populations.

Clinically trusted. Lab-ready. Patient-centric.
Sebia’s sFLC assay demonstrates real-world improvements in clinical utility and specificity—making it a superior alternative in ambiguous diagnostic scenarios involving monoclonal gammopathies.

Download the study summary or scan the QR code to view the full peer-reviewed publication.

White Paper from   Brought to you by: